Holen Sie sich die Stockscreener-App
82.93
1.18%
-0.99
Schlusskurs vom Vortag:
$83.92
Offen:
$84.67
24-Stunden-Volumen:
1.14M
Relative Volume:
1.66
Marktkapitalisierung:
$5.38B
Einnahmen:
$569.61M
Nettoeinkommen (Verlust:
$-23.36M
KGV:
-6.0959
EPS:
-13.6043
Netto-Cashflow:
$54.87M
1W Leistung:
-7.55%
1M Leistung:
-16.93%
6M Leistung:
-11.94%
1J Leistung:
+15.58%
1-Tages-Spanne:
$81.41
$84.68
1-Wochen-Bereich:
$81.41
$91.25
52-Wochen-Spanne:
$63.23
$130.00
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Firmenname
Mirum Pharmaceuticals Inc
Sektor
Branche
Telefon
650-667-4085
Adresse
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
82.93 | 5.82B | 569.61M | -23.36M | 54.87M | -13.60 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-09-24 | Eingeleitet | TD Cowen | Buy |
| 2025-08-11 | Fortgesetzt | Stifel | Buy |
| 2025-05-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2024-04-17 | Eingeleitet | Stifel | Buy |
| 2023-12-18 | Bestätigt | H.C. Wainwright | Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-13 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-09-20 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2021-09-20 | Eingeleitet | JP Morgan | Overweight |
| 2020-08-07 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-06-25 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-08-12 | Eingeleitet | Citigroup | Buy |
| 2019-08-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-08-12 | Eingeleitet | Guggenheim | Buy |
| 2019-08-12 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Mirum Pharmaceuticals Inc Aktie (MIRM) Neueste Nachrichten
Mirum Pharmaceuticals Is Maintained at Outperform by Baird - Moomoo
EBITDA of Mirum Pharmaceuticals, Inc. – HAN:08D - TradingView
Mirum's Brelovitug Meets Goal in Phase III AZURE-1 Study in HDV - Zacks Investment Research
Is Mirum Pharmaceuticals (MIRM) Undervalued On New Brelo Vitug Trial Data? - Yahoo Finance
Mirum's liver infection drug lowers virus levels in late-stage study - reuters.com
Citizens raises Mirum Pharmaceuticals stock price target on HDV data By Investing.com - Investing.com Canada
Mirum Pharmaceuticals, Meta, Boeing - TradingView
HC Wainwright & Co. maintains Buy rating on Mirum Pharmaceuticals, $195 price target - TradingView
Stifel reiterates Mirum Pharmaceuticals stock rating on trial data By Investing.com - Investing.com Canada
Mirum Pharmaceuticals Announces FDA Approval of Atebrioz and Positive Phase 3 Data for Hepatitis Delta - Kalkine Media
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis DeltaSlideshow (NASDAQ:MIRM) 2026-09-28 - Seeking Alpha
FDA nod for Mirum’s Atebrioz makes 3 options for ultra-rare bone disease - biospace.com
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment - Benzinga
What Does Mirum Pharmaceuticals's (NASDAQ:MIRM) Latest Move Mean for Healthcare Stocks Investors? - Kalkine Media
Mirum Pharmaceuticals, Inc. Meets Primary Endpoint In Phase 3 AZURE-1 Study Of Brelovitug In Chronic Hepatitis Delta Virus - marketscreener.com
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026 - Business Wire
Mirum Pharma wins FDA nod for Atebrioz - thepharmaletter.com
Mirum and Incyte gain approval of zilurgisertib for rare bone disorder - Seeking Alpha
MIRM5806400 Bond Profile: Coupon and Redemption - TradingView
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older - Mugglehead Investment Magazine
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva - Business Wire
Mirum Pharmaceuticals wins Bay Area's 14th drug approval this year - The Business Journals
Why is Mirum Pharmaceuticals stock gaining today? By Investing.com - Investing.com Canada
US FDA approves Mirum's drug for rare bone disorder - reuters.com
Bay Area company readies for decision on drug to treat alarming 'stone man' syndrome - The Business Journals
Mirum Pharmaceuticals (MIRM) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
Mirum Pharmaceuticals stock trades at USD 98.22 as targets reach USD 137.31 - AD HOC NEWS
(MIRM) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer - Contract Pharma
Mirum Pharmaceuticals stock pulls back as Bank of America reveals new stake and valuation stays belo - AD HOC NEWS
Mirum Pharmaceuticals Falls 7.1% as Investors Appear to Reassess Near-Term Biotech Catalysts - moomoo.com
Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related Events - Seeking Alpha
Mirum Pharmaceuticals at Morgan Stanley conference: growth meets key catalysts - Investing.com Canada
Mirum Pharmaceuticals Chief Financial Officer Sold Shares Worth Over $978K - TradingView
Mirum Pharma (MIRM) officer to sell shares to cover equity taxes - Stock Titan
Mirum Pharmaceuticals (MIRM) CFO offloads shares after RSUs vest - Stock Titan
Mirum Pharmaceuticals at H.C. Wainwright conference: growth, catalysts By Investing.com - Investing.com UK
Mirum Pharmaceuticals: The September PDUFA Is The Smallest Catalyst - Seeking Alpha
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Citizens reiterates Mirum Pharmaceuticals stock rating at outperform By Investing.com - Investing.com Canada
Precision Trading with Mirum Pharmaceuticals Inc. (MIRM) Risk Zones - Stock Traders Daily
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead By Investing.com - Investing.com Nigeria
Mirum Pharmaceuticals at Citi summit: dense catalyst calendar ahead - Investing.com India
Mirum Pharmaceuticals at Cantor healthcare conference: rare-disease push By Investing.com - Investing.com South Africa
Mirum Pharmaceuticals Hires LMH Strategic Solutions - Legis1
Mirum Pharmaceuticals, Inc. Announces Management Changes - marketscreener.com
Chief medical shake-up at Mirum Pharmaceuticals (NASDAQ: MIRM) includes new leader and exit deal - Stock Titan
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer - Yahoo Finance
MIRM stock gains on strong Q2 2026 revenue growth - ad-hoc-news.de
Mirum Pharmaceuticals SVP Howe Jolanda Disposes of 658 Shares at $100 Each (NASDAQ: MIRM) - Kalkine Media
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report? - Yahoo Finance
Finanzdaten der Mirum Pharmaceuticals Inc-Aktie (MIRM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Mirum Pharmaceuticals Inc-Aktie (MIRM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BJERKHOLT ERIC | CHIEF FINANCIAL OFFICER |
Sep 14 '26 |
Sale |
98.37 |
9,943 |
978,093 |
44,745 |
| Howe Jolanda | SVP, GLOBAL CONTROLLER |
Sep 02 '26 |
Sale |
100.00 |
658 |
65,800 |
616 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Sep 01 '26 |
Option Exercise |
2.94 |
30,000 |
88,080 |
224,440 |
| Peetz Christopher | CHIEF EXECUTIVE OFFICER |
Sep 01 '26 |
Sale |
98.68 |
30,000 |
2,960,401 |
194,440 |
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):